MSRV GNbAC1 from GeNeuro
Posted: Tue Feb 17, 2015 9:17 am
From their newsletter: (This is about therapy for MSRV or MS retrovirus.)
GNbAC1 has successfully completed Phase I in healthy volunteers showing that GNbAC1 is very well tolerated. GNbAC1 has also successfully completed Phase IIa last year, demonstrating an optimal safety profile and encouraging signs of efficacy on a first mall cohort of MS patients.
Information about the clinical trials are posted on http://www.clinicaltrials.gov,
identifiers NCT01639300 & NCT01699555.
A multicentric Phase IIb study in MS to test GNbAC1 is in preparation. Recruitment is expected to begin by the end 2015
GeNeuro launched two years ago longitudinal epidemiological studies to follow the evolution of the HERV proteins in populations of MS patients and healthy controls. The recruitment and following of participants are now closed. Analysis of samples will be performed within following months.
Information are posted on http://www.clinicaltrials.gov, identifiers NCT01804660
& NCT01804647.
Regulatory toxicology, Phase I Phase IIa CMC Preclinical Development Clinical Development GNbAC1 Fully funded through Phase III Multiple Sclerosis Proof-of-concept Phase IIa trial in preparation GNbAC1 Inflammatory schizophrenia CHMP (Committee for Medicinal Products for Human Use) green light for proof-of-concept trial GNbAC1
GeNeuro will present its scientific developments at the
following meetings:
International Workshop on Human Endogenous Retroviruses
and Diseases, 26-27 May 2015, Lyon – France
GeNeuro will receive the Innovation Trophee of the CCIFS
(Chambers of commerce and industry France-Switzerland), 20
February 2015, Montreux - Switzerland